Loading...
XKRX003520
Market cap241mUSD
Dec 27, Last price  
1,945.00KRW
1D
-0.61%
1Q
-17.93%
Jan 2017
-77.95%
Name

Yungjin Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:003520 chart
P/E
—
P/S
1.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.22%
Rev. gr., 5y
4.73%
Revenues
234.90b
+7.57%
109,659,792,000110,865,010,000103,376,306,000116,317,389,550112,105,475,000137,688,400,340156,622,683,050167,569,401,350170,203,311,310193,133,853,130195,008,846,800186,408,689,480220,516,292,420208,463,639,670196,067,241,850218,380,987,420234,902,460,182
Net income
-3.88b
L-82.35%
-14,580,311,000-6,733,543,000-4,347,977,000-2,308,665,7302,580,830,0001,794,227,97011,742,329,880909,091,9503,386,324,3304,202,183,1201,867,719,950-6,100,940,1105,029,923,810-133,121,310-11,582,456,190-21,961,039,430-3,875,543,360
CFO
-12.50b
L+7.66%
-1,338,311,0007,293,678,000-20,150,00010,008,673,3308,496,954,0002,379,190,2905,953,588,4206,216,130,7108,801,551,2303,111,936,5003,151,782,2301,274,179,0809,282,594,81014,497,598,2608,367,764,390-11,609,700,240-12,499,480,143
Earnings
Jan 17, 2025

Profile

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea. It provides cephalosporin antibiotic, antipsychotic, cardiovascular, and nutrition products. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. is a subsidiary of KT&G Corporation.
URL
http://www.yungjin.co.kr/
IPO date
Jun 25, 1973
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
234,902,460
7.57%
218,380,987
11.38%
196,067,242
-5.95%
Cost of revenue
198,739,556
190,442,318
175,201,287
Unusual Expense (Income)
NOPBT
36,162,904
27,938,670
20,865,955
NOPBT Margin
15.39%
12.79%
10.64%
Operating Taxes
(42,353)
(851,732)
(2,561,156)
Tax Rate
NOPAT
36,205,257
28,790,402
23,427,111
Net income
(3,875,543)
-82.35%
(21,961,039)
89.61%
(11,582,456)
8,600.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
26,014,856
11,735,265
10,906,661
Long-term debt
42,371,430
28,280,886
3,919,491
Deferred revenue
Other long-term liabilities
21,046,154
35,995,160
38,727,925
Net debt
55,557,004
37,440,827
11,614,941
Cash flow
Cash from operating activities
(12,499,480)
(11,609,700)
8,367,764
CAPEX
(10,237,537)
(13,200,150)
(11,319,769)
Cash from investing activities
(13,019,745)
(13,352,332)
(11,637,610)
Cash from financing activities
32,044,683
25,179,714
3,306,730
FCF
32,825,920
19,770,780
30,411,493
Balance
Cash
10,207,712
682,254
464,571
Long term investments
2,621,570
1,893,071
2,746,639
Excess cash
1,084,158
Stockholders' equity
73,625,753
79,296,672
94,311,943
Invested Capital
176,476,386
165,186,417
156,672,693
ROIC
21.19%
17.89%
14.74%
ROCE
20.37%
16.91%
13.32%
EV
Common stock shares outstanding
182,892
182,892
182,892
Price
2,125.00
-34.62%
3,250.00
-38.56%
5,290.00
-34.20%
Market cap
388,646,465
-34.62%
594,400,476
-38.56%
967,501,082
-34.20%
EV
444,203,469
631,841,302
979,116,023
EBITDA
44,855,710
35,718,627
28,243,803
EV/EBITDA
9.90
17.69
34.67
Interest
2,875,009
736,565
208,968
Interest/NOPBT
7.95%
2.64%
1.00%